Core Scientific (CORZ) Current Deferred Revenue (2021 - 2026)

Core Scientific has disclosed Current Deferred Revenue across 6 years of filings, most recently posting $287.2 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 91.31% year-over-year to $287.2 million; the TTM figure through Jun 2026 stood at $287.2 million (up 91.31% YoY), while the FY2025 annual figure was $127.6 million, up 603.44% from the prior year.
• Current Deferred Revenue came in at $287.2 million for Q2 2026 at Core Scientific, down from $654.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $654.2 million in Q1 2026 to a low of $7.9 million in Q2 2024.
• Average Current Deferred Revenue over 5 years is $121.9 million, with a median of $92.3 million recorded in 2023.
• Year-over-year, Current Deferred Revenue plunged 93.84% in 2023 and surged 1797.46% in 2025.
• Over 5 years, Current Deferred Revenue stood at $159.6 million in 2022, then sank by 93.84% to $9.8 million in 2023, then surged by 84.48% to $18.1 million in 2024, then surged by 603.44% to $127.6 million in 2025, then soared by 125.15% to $287.2 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $287.2 million in Q2 2026, $654.2 million in Q1 2026, and $127.6 million in Q4 2025.